Antimyuller gormoni (AMH)
Kod:9050|CPT:82166|LOINC:38476-8
| Kabi | Antimyuller gormoni (AMH) |
|---|
Tahlil ma'lumotlari
Tadqiqot usuli
- Elektrokimyoluminessent immunoanaliz (ECLIA)
- Kimyoluminessent immunoanaliz (CLIA)
Kutilayotgan natija topshirish vaqti
1–2 kun
Maxsus tayyorlik
- Infants younger than 1 year: do not feed for 30–40 minutes before the blood draw
- Children 1–5 years: avoid food for 2–3 hours prior to collection
- Adults: fast for 12 hours; water is allowed
- With clinician approval, withhold estrogens and androgens for 48 hours before specimen collection
- Do not smoke during the 30 minutes before collection
Qanday foydalanish
Antimyuller gormoni (AMH) tahlili, Myuller yo‘llarini inhibitsiyalovchi gormon (MIH) yoki Myuller inhibitsiyalovchi omil (MIS) nomlari bilan ham ma’lum, tuxumdon zaxirasini baholash va tuxumdon stimulyatsiyasiga javobni taxminlash hamda tuxumdonlarning giperstimulyatsiya sindromi xavfini baholash orqali yordamchi reproduktiv texnologiyani individualizatsiya qilish uchun qo‘llanadi. AMH hayz sikli davomida nisbatan kam o‘zgaradi va antral follikulalar soni kabi ultratovushga asoslangan ko‘rsatkichlarni to‘ldiradi. AMH tekshiruvi jinsiy rivojlanish buzilishlarini baholashga yordam beradi, jumladan, tushmagan moyaklarni anorxiyadan farqlash va persistiruvchi Myuller yo‘llari sindromini ko‘rib chiqish. U obstruktiv va noobstruktiv azospermiyani differensial diagnostika qilishga hissa qo‘shadi va granuloza-hujayrali hamda Sertoli-hujayrali o‘smalar uchun diagnostik baholash va davolash monitoringida marker bo‘lib xizmat qiladi.
Cheklovlar
AMH sekretsiyasi Sertoli hujayralarida homiladorlikning taxminan 7-haftasidan boshlanadi va erkak jinsiy differensiasiyasi davomida Myuller yo‘llarining regressiyasini boshqaradi. AMH yetishmovchiligi yoki uning retseptoridagi nuqsonlar, ichki va tashqi jinsiy a’zolari boshqa jihatdan normal bo‘lishiga qaramay, Myuller yo‘llari hosilalarining persistensiyasiga olib kelishi mumkin. AMH moyaklarning tushishida ishtirok etadi; past yoki aniqlanmaydigan AMH darajasi kriptorkizmni baholashda anorxiyani qo‘llab-quvvatlaydi, o‘lchanadigan daraja esa moyak to‘qimasi mavjudligini ko‘rsatadi. Erkaklarda aylanma AMH go‘daklik davrida yuqori, bolalik va o‘smirlik davomida pasayadi va kattalikda past darajada qoladi. Ayollarda AMH o‘sayotgan follikulalarning granuloza hujayralari tomonidan ishlab chiqariladi; u primordial follikulalarning jalb etilishini inhibitsiya qiladi va follikulaning FSH ga sezgirligini modulyatsiya qiladi. Konsentratsiyalar go‘daklik va bolalikda juda past, pubertat davrida biroz ko‘tariladi va yosh o‘tishi bilan bosqichma-bosqich kamayadi, menopauzadan keyin aniqlanmaydi. Qon zardobidagi AMH o‘sayotgan follikulalar havzasini aks ettiradi va funksional tuxumdon zaxirasi bilan korrelyatsiyalanadi; bu zaxira yosh o‘tishi bilan va gonadotoksik terapiyalardan so‘ng kamayadi. Klinik jihatdan, AMH yordamchi reproduktsiya protokollarini tanlash va monitoring qilishga yordam beradi, kutilayotgan past javob beruvchilar va giperjavob beruvchilarni aniqlash orqali. Shuningdek, u granuloza-hujayrali tuxumdon o‘smalari va kamroq uchraydigan Sertoli-hujayrali o‘smalarni, giperestrogenizm bilan namoyon bo‘lishi mumkin bo‘lgan holatlarda, tashxislash va uzoq muddatli monitoring uchun foydalidir.
| O'lchov birligi | ng/mL |
|---|---|
| Referens oraliq | — |
| Ko'rsatmalar | Workup of cryptorchidism in male infants, including distinction between undescended testes and anorchia, Assessment of ambiguous genitalia and broader disorders of sex development, Differentiation of obstructive versus nonobstructive azoospermia, Evaluation of ovarian reserve and projection of reproductive lifespan, including the timing of infertility and menopause, Stratification of expected ovarian response to controlled ovarian stimulation and estimation of ovarian hyperstimulation syndrome risk in ART, Investigation of hyperestrogenic states (eg, abnormal uterine bleeding in women; gynecomastia in men) |
Namunangiz talablari
| Namunangiz | Zardob |
|---|---|
| Container | Oltin/yo'lbars qopqoqli probirka (SST, gel ajratgich) |
| Hajm | 5 mL (min 2.3 mL) |
| Saqlash tayyorlik | Xona harorati, Sovutilgan, Muzlatilgan |
References
Tal R, Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol. 2017 Feb;1-12. PubMed 28235465 10.1016/j.ajog.2017.02.027
Practice Committee of the American Society for Reproductive Medicine (ASRM). Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015 Mar;103(3):e9-e17. PubMed 25585505 10.1016/j.fertnstert.2014.12.093
Zegers-Hochschild F, Adamson GD, Dyer S, et al. The International Glossary on Infertility and Fertility Care, 2017. Fertil Steril. July 2017:1-15. PubMed 28760517 10.1016/j.fertnstert.2017.06.005
Leader B, Hegde A, Baca Q, et al. High frequency of discordance between antimullerian hormone and follicle stimulating hormone levels in serum from estradiol confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril. 2012 Oct;98(4):1037-1042. PubMed 22771028 10.1016/j.fertnstert.2012.06.006
Ahmed SF, Rodie M. Investigation and initial management of ambiguous genitalia. Best Pract Res Clin Endocrinol Metab. 2010 Apr;24(2):197-218.
Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005 Apr 29;234(1–2):81–6.
Lambalk CB, van Disseldorp J, de Koning CH. Testing ovarian reserve to predict age at menopause. Maturitas. 2009 Aug 20;63(4):280-91.
La Marca A, Volpe A. The Anti-Mullerian hormone and ovarian cancer. Hum Reprod Update. 2007 May-Jun;13(3):265-73.
Rey R, Sabourin JC, Venara M. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Hum Pathol. 2000 Oct;31(10):1202-8.